{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T18:10:34Z","timestamp":1769969434256,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jinf.2019.03.003","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T21:01:59Z","timestamp":1551819719000},"page":"402-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics"],"prefix":"10.1016","volume":"78","author":[{"given":"Fred S.","family":"Sarfo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuri","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Feldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Incardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Lwanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Sonnerborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tafese B.","family":"Tufa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2019.03.003_bib0001","unstructured":"Joint United Nations programme on HIV\/AIDS (UNAIDS) AIDSInfo online database. Geneva, Switzerland: UNAIDS; 2015. Available from: www.aidsinfoonline.org. Accessed 26 December 2017."},{"key":"10.1016\/j.jinf.2019.03.003_bib0002","series-title":"Recommendations for a public health approach","year":"2013"},{"key":"10.1016\/j.jinf.2019.03.003_bib0003","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","article-title":"Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review","volume":"10","author":"Barth","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2019.03.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111400","article-title":"Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy","volume":"9","author":"Sarfo","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jinf.2019.03.003_bib0005","doi-asserted-by":"crossref","first-page":"e72152","DOI":"10.1371\/journal.pone.0072152","article-title":"High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in rural HIV treatment programme in KwaZulu-Natal, South Africa","volume":"8","author":"Manasa","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jinf.2019.03.003_bib0006","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/S2352-3018(15)00087-9","article-title":"IeDEA southern Africa, east Africa, and west Africa. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis","volume":"2","author":"Haas","year":"2015","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.jinf.2019.03.003_bib0007","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N Eng J Med"},{"issue":"17","key":"10.1016\/j.jinf.2019.03.003_bib0008","first-page":"30630","article-title":"Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomized controlled trial","volume":"S1473-3099","author":"Hakim","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2019.03.003_bib0009","article-title":"Effectiveness of protease inhibitor\/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of HIV-1 infection in sub-Saharan Africa: systematic review and meta-analysis","author":"Stockdale","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2019.03.003_bib0010","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3018(17)30109-1","article-title":"Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV\/AIDS: a systematic review and network meta-analysis","volume":"4","author":"Kanters","year":"2017","journal-title":"Lancet HIV"},{"issue":"8","key":"10.1016\/j.jinf.2019.03.003_bib0011","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328351f5b2","article-title":"Treatment outcomes of patients on second-line therapy in resource-limited settings: a systematic review and meta-analysis","volume":"26","author":"Ajose","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2019.03.003_bib0012","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1468-1293.2010.00825.x","article-title":"Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline","volume":"11","author":"Hosseinipour","year":"2010","journal-title":"HIV Med"},{"key":"10.1016\/j.jinf.2019.03.003_bib0013","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/QAI.0b013e3181bcdac1","article-title":"High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa","volume":"53","author":"Fox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2019.03.003_bib0014","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/QAD.0b013e3283333639","article-title":"Outcomes after virologic failure of first-line ART in South Africa","volume":"24","author":"Murphy","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2019.03.003_bib0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3851\/IMP1819","article-title":"Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa","volume":"16","author":"Levison","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jinf.2019.03.003_bib0016","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32833a097b","article-title":"Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa","volume":"24","author":"El-Khatib","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2019.03.003_bib0017","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/QAI.0b013e31820dc0cc","article-title":"Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting","volume":"56","author":"van Zyl","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.jinf.2019.03.003_bib0018","doi-asserted-by":"crossref","first-page":"e58526","DOI":"10.1371\/journal.pone.0058526","article-title":"Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa","volume":"8","author":"Schoffelen","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jinf.2019.03.003_bib0019","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3018(16)00016-3","article-title":"Estimating the need of second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical model","volume":"3","author":"Estill","year":"2016","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.jinf.2019.03.003_bib0020","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(14)00061-7","article-title":"Baseline HIV-resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis","volume":"2","author":"Boyd","year":"2015","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.jinf.2019.03.003_bib0021","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in health volunteers","volume":"48","author":"La Porte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jinf.2019.03.003_bib0022","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3851\/IMP1757","article-title":"Lopinavir exposure is in sufficient in children given double doses of lopinavir\/ritonavir during rifampicin-based treatment for tuberculosis","volume":"16","author":"McIlleron","year":"2011","journal-title":"Antivir Ther"},{"issue":"9240","key":"10.1016\/j.jinf.2019.03.003_bib0023","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0140-6736(00)02876-2","article-title":"HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts","volume":"356","author":"Bowen","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2019.03.003_bib0024","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/2050-6511-15-61","article-title":"Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV-infected tuberculosis patients on lopinavir\/ritonavir-based antiretroviral therapy","volume":"15","author":"Nalker","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.jinf.2019.03.003_bib0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dku382","article-title":"Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir\/ritonavir","volume":"70","author":"Moultrie","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jinf.2019.03.003_bib0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","article-title":"Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","volume":"62","author":"Dooley","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.jinf.2019.03.003_bib0027","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3851\/IMP1719","article-title":"Virological characterization of patients failing darunavir\/ritonavir or lopinavir\/ritonavir treatment in the ARTEMIS study: 96-week analysis","volume":"16","author":"Lathouwers","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jinf.2019.03.003_bib0028","article-title":"Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir\/r-containing antiretroviral therapy in South Africa","volume":"2011","author":"Wallis","year":"2011","journal-title":"AIDS Res Treat"},{"issue":"8","key":"10.1016\/j.jinf.2019.03.003_bib0029","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomized, open-label, EARNEST trial","volume":"4","author":"Paton","year":"2017","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.jinf.2019.03.003_bib0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/QAI.0b013e3182615ad1","article-title":"Second-line antiretroviral therapy: long-term outcomes in South Africa","volume":"61","author":"Murphy","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.jinf.2019.03.003_bib0031","doi-asserted-by":"crossref","first-page":"21218","DOI":"10.7448\/IAS.20.1.21218","article-title":"Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts","volume":"20","author":"Bijker","year":"2017","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.jinf.2019.03.003_bib0032","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1570162X13666150825123750","article-title":"Longitudinal analysis of adherence to first-line antiretroviral therapy: evidence of treatment sustainability from an Indian HIV cohort","volume":"14","author":"Shet","year":"2016","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.jinf.2019.03.003_bib0033","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12882-015-0192-4","article-title":"Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana","volume":"16","author":"Chadwick","year":"2015","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/j.jinf.2019.03.003_bib0034","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jinf.2013.03.008","article-title":"High prevalence of renal dysfunction and association with risk of death amongst HIV-infected Ghanaians","volume":"67","author":"Sarfo","year":"2013","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.jinf.2019.03.003_bib0035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jinf.2018.03.001","article-title":"Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV\/HBV positive adults in Ghana","volume":"76","author":"Villa","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2019.03.003_bib0036","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2018.12.026","article-title":"Burden of subclinical carotid atherosclerosis and vascular risk factors among people living with HIV in Ghana","volume":"397","author":"Sarfo","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jinf.2019.03.003_bib0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2018.09.021","article-title":"Risk factors for stroke occurrence in a low HIV endemic West African country: a case-control study","volume":"395","author":"Sarfo","year":"2018","journal-title":"J Neurol Sci"},{"issue":"9","key":"10.1016\/j.jinf.2019.03.003_bib0038","doi-asserted-by":"crossref","first-page":"e940","DOI":"10.1016\/S2214-109X(18)30305-X","article-title":"Dyslipidemia among African adults","volume":"6","author":"Sarfo","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jinf.2019.03.003_bib0039","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2018.09.018","article-title":"Incident stroke among Ghanaians with hypertension and diabetes: a multicenter, prospective cohort study","volume":"395","author":"Sarfo","year":"2018","journal-title":"J Neurol Sci."},{"issue":"4","key":"10.1016\/j.jinf.2019.03.003_bib0040","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/S2214-109X(18)30002-0","article-title":"Dominant modifiable risk factors for stroke in Ghana and Nigeria (SIREN): a case-control study","volume":"6","author":"Owolabi","year":"2018","journal-title":"Lancet Glob Health"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445319300726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445319300726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:27:09Z","timestamp":1759008429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445319300726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0163445319300726"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2019.03.003","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2019.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}